Genmab Licenses Angiogenesis Targets from Bionomics
News Feb 15, 2006
Under the agreement, Genmab has acquired exclusive worldwide rights to eight proteins identified and characterized by Bionomics using its proprietary Angene® angiogenesis platform with potential utility in cancer and other diseases.
Under the terms of the deal, Bionomics will receive an upfront fee and additional fees upon the first target achieving specified preclinical and clinical milestones.
Bionomics will also receive milestone payments and royalties on product sales for each product that reaches the market.
The agreement represents the outcome of an earlier collaborative research and development partnership between the companies.
"We are pleased to exclusively license these targets from Bionomics, with which we have had an excellent working relationship since early 2002," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.
"We believe that inhibiting angiogenesis bears promise for the development of antibody therapeutic approaches in angiogenesis-related diseases including cancer. These targets enrich and further strengthen Genmab’s growing pre-clinical pipeline."
"We believe that Genmab is the ideal partner to develop these targets," commented Deborah Rathjen, Bionomics’ Managing Director and CEO.
"Genmab has rights to the key intellectual property required for the development of antibody therapeutics, and, with six products in the clinic, it has a strong record of clinical development."
Bionomics will retain rights to a large number of additional proprietary proteins it has discovered in its angiogenesis program, including, BNO69. Bionomics is continuing to develop BNO69 as a target for small molecule therapeutics for the treatment of breast cancer.
The agreement will not influence Genmab’s financial guidance for 2006 which will be presented on February 16, 2006.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE